公开(公告)号：US20040224906A1

公开(公告)日：2004-11-11

申请号：US10862542

申请日：2004-06-07

发明人： Hendrik Derk Hoving ,  Hans Robert Kattenberg ,  Dick Antonius Johannes Starmans

IPC分类号： A61K031/7048 ,  C07H017/00

CPC分类号： A23G1/30 ,  A23G1/48 ,  A23G3/36 ,  A23G3/48 ,  A23G9/32 ,  A23G9/42 ,  A23L3/3472 ,  A23L3/349 ,  A23L33/105 ,  A61K8/97 ,  A61K36/00 ,  A61K36/185 ,  A61K2800/522 ,  A61Q19/00 ,  C07D311/62

摘要： Water soluble antioxidant composition derived from natural sources having less than 10 ppm chlorinated hydrocarbons, less than 0.5% by weight fat, at least 15% by weight in total polyphenolic antioxidants, less than 5% by weight purine components, less than 0.5% by weight caffeine, and a Trolox Equivalent Antioxidant Capacity value of at least 0.4. The composition is suitable for use in pharmaceuticals, cosmetic, and nutritional compositions.

摘要翻译： 衍生自天然来源的水溶性抗氧化剂组合物，其具有小于10ppm氯化烃，小于0.5重量％的脂肪，至少15重量％的总酚类抗氧化剂，小于5重量％的嘌呤成分，小于0.5重量％ 咖啡因和Trolox当量抗氧化能力值至少为0.4。 该组合物适用于药物，化妆品和营养组合物。

公开(公告)号：US20040006793A1

公开(公告)日：2004-01-08

申请号：US10352773

申请日：2003-01-28

发明人： Margaret Y. Gruber ,  Heather Ray

IPC分类号： A01H001/00 ,  C12N015/82 ,  C12Q001/68 ,  C07H021/04 ,  C07H017/00 ,  C12N009/24 ,  C12N005/04

CPC分类号： C12N15/825 ,  C07K14/415 ,  C12N15/8243

摘要： The present invention provides two novel regulatory genes and encoded proteins which can be used to alter the biosynthesis and accumulation of condensed tannin levels in plants and plant tissues. The present invention further encompasses transgenic constructs containing the novel regulatory genes herein referred to as Ulimyc, Corniculmyc and Japmyc, for use in the transformation of plants and plant tissues and transgenic plants containing such constructs. The identification and characterization of these novel genes provide a mechanism for altering tannin production in plants and allows one to alter such levels to produce a variety of benefits in the field of agriculture, land reclamation animal farming and food technology in general.

摘要翻译： 本发明提供了两种新的调控基因和编码的蛋白质，其可用于改变植物和植物组织中浓缩单宁水平的生物合成和积累。 本发明还包括含有本文中称为Ulimyc，Corniculmyc和Japmyc的新调节基因的转基因构建体，用于转化植物和植物组织以及含有这种构建体的转基因植物。 这些新型基因的鉴定和表征提供了改变植物中单宁生产的机制，并且允许改变这些水平以在农业，土地开垦动物养殖和食品技术领域产生各种益处。

公开(公告)号：US20030083270A1

公开(公告)日：2003-05-01

申请号：US10246112

申请日：2002-09-18

申请人： ROCHE VITAMINS, INC.

发明人： David Carl Burdick ,  Heinz Egger ,  Andrew George Gum ,  Ingo Koschinski ,  Elena Muelchi ,  Isabelle Prevot-Halter

IPC分类号： A61K031/7048 ,  A61K031/353 ,  C07D311/74 ,  C07H017/00

CPC分类号： C07D311/62 ,  A23F3/205 ,  C07H17/00

摘要： A process is provided for making (-)-epigallocatechin gallate (EGCG) by subjecting a green tea extract to chromatography on a macroporous polar resin, eluting EGCG from the resin with a polar elution solvent, optionally concentrating the eluate, optionally regenerating the resin by desorbing the remaining catechins, and optionally concentrating the desorbed catechins.

摘要翻译： 提供一种制备（ - ） - 表没食子儿茶素没食子酸酯（EGCG）的方法，该方法是使绿茶提取物在大孔极性树脂上进行色谱分离，用极性洗脱溶剂从树脂中洗脱EGCG，任选地浓缩洗脱液，任选地通过 解吸剩余的儿茶素，并且可选地浓缩解吸的儿茶素类。

公开(公告)号：US20020147317A1

公开(公告)日：2002-10-10

申请号：US10094678

申请日：2002-03-11

申请人： 3M Innovative Propeties Company

发明人： James Gregory Bentsen ,  Christopher Allen Mickelson ,  Orlin Bruce Knudson ,  Kevin Michael Lewandowski

IPC分类号： C07K014/435 ,  C07H017/00 ,  C07D47/02

CPC分类号： C07H17/075 ,  C12Q1/04 ,  C12Q1/34 ,  C12Q2334/20 ,  G01N2333/924

摘要： Disclosed are novel coumarin based fluorogenic compounds useful in assaying for biological activity. Specifically, these fluorogenic compounds exhibit fluorescence at particular wavelengths when cleaved by target enzymes. Preferred compounds include sugar and peptide derivatives of umbelliferone derivatives bearing a heterocyclic five membered ring at the 3-position. These compounds can be used for rapidly detecting food pathogens and for determining sterilization effectiveness. The compounds may also be used in a form bounded to a polymeric support or to a biomolecule or macromolecule.

摘要翻译： 公开了可用于测定生物活性的新型基于香豆素的荧光化合物。 具体地说，当目标酶切割时，这些荧光化合物在特定波长处表现出荧光。 优选的化合物包括在3位具有杂环五元环的伞形酮衍生物的糖和肽衍生物。 这些化合物可用于快速检测食物病原体和确定灭菌效果。 化合物也可以以与聚合物载体或生物分子或大分子结合的形式使用。

公开(公告)号：US20020058288A1

公开(公告)日：2002-05-16

申请号：US09043255

申请日：1998-08-06

发明人： MARCUS JOSEPHUS MARIE KOOLEN ,  JAN BAS LOUIS DAMM ,  BORIS STRIEPEN ,  RALPH T. SCHWARZ

IPC分类号： C07H015/00 ,  C07G011/00 ,  C07G003/00 ,  C07H017/00 ,  G01N033/53 ,  G01N033/567 ,  G01N033/569 ,  A61K039/395 ,  C12N005/06 ,  C12N005/16

CPC分类号： A61K39/002 ,  C07H3/06 ,  C07K16/20

摘要： The present invention relates to a glycoconjugate immunoreactive with Toxoplasma gondii antibodies, (monoclonal) antibodies against these glycoconjugates, and cell lines capable of producing monoclonal antibodies. The invention is further concerned with immunochemical reagents and methods for the detection of T. gondii or antibodies directed agains T. gondii. Furthermore the invention relates to a therapeutic reagent for the inhibition of replication of T. gondii parasites and a method for the production of a live attenuated T. gondii vaccine. It has now been found, and in contrast with earlier publications in this art, that several glycoconjugates are immunoreactive with Toxoplasma gondii specific antibodies comprising a glycan core structure having general formula (I) wherein R1nullHydrogen, nullPO 3 nullCH 2 nullCH 2 nullNH 2 (ethanolamine-phosphate), or nullPO 3 nullCH 2 nullCH 2 nullNHnullX, wherein Xnulla T. gondii specific antigen; wherein R2nullnullnullOnullR4, null(1-4)-O-anhydromannitol or null(1-4)-O-glucoseamine optionally null(1-6)-linked to the inositol moiety of a phosphatidylinositol membrane anchor; wherein R3nulla monosaccharide moiety, wherein R4nullHydrogen or nullLnullR5, wherein Lnulla bivalent organic radical and R5nulla functional group that allows coupling to a carrier. A preferred embodiment of the monosaccharide moiety is a hexose moiety, more preferred is a glucose moiety, and most preferred is a glucose moiety which is bonded to the GalNAc-moiety by an null1,4 glycosidic bond. It has been found that the glycoconjugates according to the present invention are particularly suitable for diagnosing T. gondii infected humans.

摘要翻译： 本发明涉及与弓形体弓形体抗体免疫反应的糖缀合物，针对这些糖缀合物的（单克隆）抗体，以及能够产生单克隆抗体的细胞系。 本发明还涉及用于检测弓形虫的免疫化学试剂和方法或再次引导弓形虫的抗体。 此外，本发明涉及用于抑制弓形虫寄生虫复制的治疗试剂，以及生产活的减毒弓形虫疫苗的方法。 现在已经发现，与本领域的早期出版物相反，几种糖缀合物与弓形体特异性抗体是免疫反应性的，其包含通式（I）的聚糖核心结构，其中R1 =氢，-PO3-CH2-CH2 2 -NH 2（乙醇胺磷酸盐）或-PO 3 -CH 2 -CH 2 -NH-X，其中X =弓形虫特异性抗原; 其中R2 =±-O-R4，±（1-4）-O-脱水脱醇糖醇或±（1-4）-O-葡萄糖胺任选地±（1-6）连接到磷脂酰肌醇膜锚的肌醇部分; 其中R3 =单糖部分，其中R4 =氢或-L-R5，其中L =二价有机基团，R5 =允许与载体结合的官能团。 单糖部分的优选实施方案是己糖部分，更优选葡萄糖部分，最优选葡萄糖部分，其通过±1,4糖苷键与GalNAc部分结合。 已经发现根据本发明的糖缀合物特别适用于诊断感染弓形虫感染的人。

公开(公告)号：US20020026038A1

公开(公告)日：2002-02-28

申请号：US09736449

申请日：2000-12-15

发明人： Ilya Avrutov ,  Igor Lifshitz ,  Ronen Borochovitz ,  Basem Masarwa ,  Edi Schwartz

IPC分类号： C07H017/00

CPC分类号： C07H17/08

摘要： The present invention relates to processes for converting clarithromycin Form 0 to clarithromycin Form II, which include slurrying clarithromycin the Form 0 in water. The present invention also relates to processes for the preparation of clarithromycin Form II by converting erythromycin A to clarithromycin and thereafter converting clarithromycin Form 0 to clarithromycin Form II by slurrying. The present invention further relates to the novel clarithromycin polymorph Form IV, a process for its preparation, pharmaceutical compositions comprising the compound, and methods of using the compound as a therapeutic agent.

摘要翻译： 本发明涉及将克拉霉素形式0转化成克拉霉素II型的方法，其包括在水中将形式0的克拉霉素制浆。 本发明还涉及通过将红霉素A转化成克拉霉素来制备克拉霉素II型的方法，然后通过浆化将克拉霉素形式0转化成克拉霉素II型。 本发明还涉及新型克拉霉素多晶型IV，其制备方法，包含该化合物的药物组合物，以及使用该化合物作为治疗剂的方法。

公开(公告)号：US20040209825A1

公开(公告)日：2004-10-21

申请号：US10838766

申请日：2004-05-04

发明人： Thomas P. Lahey ,  V.J. Rajadhyaksha

IPC分类号： A61K031/7048 ,  A61K031/353 ,  C07H017/00

CPC分类号： C07D407/04 ,  A61K31/352 ,  A61K31/353 ,  C07D311/30 ,  C07D311/32 ,  C07D311/36 ,  C07D493/04 ,  C07F9/65522

摘要： 3-Deoxyflavonoid compounds and methods for inhibiting T-cell activity and treating diseases and disorders (e.g., autoimmune disorders, inflammatory disorders, diabetes, ALS, MS, rheumatoid arthritis, etc.). In some cases the efficacy and/or duration of action of luteolin and/or other 3-dioxyflavinoid compounds may be increased by administering such compounds along with Rutin, a Rutin congener and/or a Rutin derivative. Also, in some cases, first pass metabolism of luteolin or other 3-deoxyflavinoids may be avoided by administering such compounds by parenteral routes (e.g., sublingual, buccal, intranasal, injection, etc.).

摘要翻译： 3-脱氧黄酮化合物和抑制T细胞活性和治疗疾病和病症（例如自身免疫性疾病，炎症性疾病，糖尿病，ALS，MS，类风湿性关节炎等）的方法。 在一些情况下，可以通过将这些化合物与芦丁，芦丁同类物和/或芦丁衍生物一起施用来增加木犀草素和/或其它3-二氧化黄素类化合物的功效和/或作用持续时间。 此外，在一些情况下，通过肠胃外途径（例如舌下，口腔，鼻内，注射等）施用此类化合物可以避免木犀草素或其他3-脱氧黄素类的首过代谢。

公开(公告)号：US20040101933A1

公开(公告)日：2004-05-27

申请号：US10380056

申请日：2003-03-11

发明人： Hitoshi Matsumoto ,  Satoshi Hanamura ,  Masao Hirayama

IPC分类号： C12P019/60 ,  C07H017/00

CPC分类号： C07H17/00 ,  C07H17/065 ,  C09B61/00 ,  C12P19/14 ,  C12P19/44

摘要： Provided are a process for producing purified anthocyanidin glucoside in which a rhamnose end of anthocyanidin rutinoside is cleaved using rhamnosidase to convert the anthocyanidin rutinoside component into anthocyanidin glucoside, the anthocyanidin glucoside component being then purified and isolated; or a crystalline anthocyanidin glucoside salt obtained by further crystallizing the purified anthocyanidin glucoside and a process for producing the same. Also provided are a process for producing purified anthocyanidin rutinoside in which a glucose end of anthocyanidin glucoside is cleaved using null-glucosidase to degrade and remove the end, the anthocyanidin rutinoside component being then purified and isolated; or a crystalline anthocyanidin rutinoside salt obtained by further crystallizing the purified anthocyanidin rutinoside and a process for producing the same.

摘要翻译： 提供了使用鼠李糖苷酶将花色素芸香糖苷成分转化为花色素苷葡糖苷的花青素芸香糖苷的鼠李糖末端切割纯化花青素葡糖苷的方法，然后纯化和分离花色素苷苷组分; 或通过进一步结晶纯化的花青素葡糖苷而获得的结晶花色素苷糖苷及其制备方法。 还提供了生产纯化的花青素芸香糖苷的方法，其中使用β-葡糖苷酶切割花青素葡糖苷的葡萄糖末端以降解和除去末端，然后纯化和分离花色素芸香糖苷组分; 或通过进一步结晶纯化的花青素芸香苷获得的结晶花色素芸香糖苷盐及其制备方法。

公开(公告)号：US20040059100A1

公开(公告)日：2004-03-25

申请号：US10470773

申请日：2003-07-31

发明人： Herwig Buchholz ,  Sophie Perruchon

IPC分类号： C07H017/00 ,  C07D311/76

CPC分类号： C07D493/04 ,  C07D311/30

摘要： The invention relates to a process for the preparation of flavone derivatives in which a 2-hydroxyacetophenone compound is metallated using a lithium compound at low temperatures and subsequently reacted with a keto compound, and where the ratio of the molar equivalents of lithium compound to the 2-hydroxyacetophenone compound functional groups to be metallated is from 1 to 1.2. The resultant null-diketone compound is subsequently cyclised with warming in an acidic medium.

摘要翻译： 本发明涉及一种制备黄酮衍生物的方法，其中2-羟基苯乙酮化合物在低温下使用锂化合物进行金属化，随后与酮化合物反应，其中锂化合物的摩尔当量与2 - 羟基苯乙酮化合物官能团的金属化为1〜1.2。 随后在酸性介质中加温使所得的β-二酮化合物环化。

公开(公告)号：US20030100515A1

公开(公告)日：2003-05-29

申请号：US10168251

申请日：2002-09-06

发明人： Luc Lebreton ,  Christiane Legendre ,  Soth Samreth

IPC分类号： A61K031/7034 ,  C07H017/00

CPC分类号： C07H15/203

摘要： The invention concerns: (i) null4-(4-cyanobenzyl)phenylnullglycopyranosides of formula (I) wherein; the glycopyranosyl group R represents a null-D arabinopyranosyl, null-D-lyxopyranosyl, null-D-ribopyranosyl, null-D-mannopyranosyl, null-L-arabinopyranosyl, null-L-xylopyranosyl, null-L-arabinopyranosyl, null-L-xylopyranosyl or null-L-rhamnopyranosyl group; and (ii) their esters resulting from esterification of at least a OH function of each glycopyranosyl group with a C2-C4 alkanoic or cycloalkanoic acid, as novel industrial products. Said novel null4-(4-cyanobenzyl)phenylnullglycopyranosides are useful in therapy for fighting against athermatous plaque.

摘要翻译： 本发明涉及：（i）式（I）的[4-（4-氰基苄基）苯基]吡喃糖苷，其中： D-吡喃葡萄糖基，β-D-吡喃葡萄糖基，β-D-吡喃葡萄糖基，β-L-阿拉伯吡喃糖基，β-L-吡喃木糖基，α-L-阿拉伯吡喃糖基，α-L-吡喃葡萄糖基 - 羟基吡喃糖基或β-L-鼠李糖吡喃糖基; 和（ii）由C2-C4链烷酸或环链烷酸作为每个糖吡喃糖基的至少OH官能团的酯化产生的酯作为新的工业产品。 所述新型[4-（4-氰基苄基）苯基]吡喃糖苷可用于治疗抗牙釉质的治疗。